Market closed
Castle Biosciences/$CSTL
14:30
15:25
16:15
17:10
18:00
1D1W1MYTD1Y5YMAX
About Castle Biosciences
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Ticker
$CSTL
Sector
Trading on
Industry
Health Care Providers & Services
Headquarters
Employees
710
Website
CSTL Metrics
BasicAdvanced
$770M
Market cap
130.63
P/E ratio
$0.21
EPS
0.98
Beta
-
Dividend rate
Price and volume
Market cap
$770M
Beta
0.98
52-week high
$33.33
52-week low
$16.97
Average daily volume
335K
Financial strength
Current ratio
7.784
Quick ratio
7.451
Long term debt to equity
5.667
Total debt to equity
6.063
Interest coverage (TTM)
-2.13%
Management effectiveness
Return on assets (TTM)
-0.14%
Return on equity (TTM)
1.47%
Valuation
Price to earnings (TTM)
130.629
Price to revenue (TTM)
2.423
Price to book
1.74
Price to tangible book (TTM)
2.33
Price to free cash flow (TTM)
21.884
Growth
Revenue change (TTM)
62.43%
Earnings per share change (TTM)
-107.42%
3-year revenue growth (CAGR)
53.43%
3-year earnings per share growth (CAGR)
-44.64%
What the Analysts think about CSTL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Castle Biosciences stock.
CSTL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CSTL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CSTL News
AllArticlesVideos
Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett's Esophagus Patients
Business Wire·2 months ago
Castle Biosciences to Participate in Upcoming Investor Conferences
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Castle Biosciences stock?
Castle Biosciences (CSTL) has a market cap of $770M as of December 25, 2024.
What is the P/E ratio for Castle Biosciences stock?
The price to earnings (P/E) ratio for Castle Biosciences (CSTL) stock is 130.63 as of December 25, 2024.
Does Castle Biosciences stock pay dividends?
No, Castle Biosciences (CSTL) stock does not pay dividends to its shareholders as of December 25, 2024.
When is the next Castle Biosciences dividend payment date?
Castle Biosciences (CSTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Castle Biosciences?
Castle Biosciences (CSTL) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.